

ASX Announcement

Medibio Limited – 22 November 2019



Company Update

Melbourne, Australia and Minneapolis, MN – 22 November 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), advises that following the completion of the Company's 2019 Annual General Meeting (**AGM**) and as outlined in the voting results released on this day that there have been changes to the Board composition.

In light of these changes the Company did not present an update on the Company's operations or long term strategy at the AGM. The newly composed Board of Directors will review the Company's strategy and provide an update to its shareholders and stakeholders in due course.

Yours faithfully,

David B. Kaysen

Chairman, Managing Director and CEO
Medibio Limited

-ENDS-

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental wellbeing solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:		Website: www.medibio.com.au	
Medibio Media Enquiries: Kristi Hamilton Director, Strategic Communications Medibio Limited kristi.hamilton@medibio.com.au T: +1 952 232 0934		Australian Investor Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231	